

Immunotherapy/Nivolumab Trials

June 2018

City	Protocol	Title	Tumor Group	Trial Phase	NCT	Open Date
Edmonton	Small Molecule Study	Developing Novel Cancer Immunotherapy Drugs: A Multidisciplinary Team	Melanoma	Obsrv		02-Dec-15
Edmonton	CA 209 915	A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Ipilimumab or Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma	Melanoma	Phase III	NCT03068455	19-Jul-17
Edmonton	BMS CA209-9GW	Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined with Daratumumab in Participants with Advanced or Metastatic Solid Tumours	Phase I	Phase I/II	NCT03098550	05-Dec-17
Edmonton	CV202-103	A Phase 1b/2 Study of BMS-813160 in Combination with Chemotherapy or Nivolumab in Patients with A dvanced Solid Tumors	Phase I	Phase I/II	NCT03184870	18-Mar-18
Edmonton	CA 209 227	An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)	Lung	Phase III	NCT02477826	17-Mar-16
Edmonton	CA 017 003	A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (BMS-936558, anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors	Phase I	Phase I/II	NCT02658890	12-May-16
Edmonton	IIT-RATIO	Microarray Prediction of Response to Nivolumab, Ipilimumab, or Combined Therapy in Subjects with Previously Untreated, Locally Advanced or Metastatic Melanoma	Melanoma	Other	NCT02700971	29-Jun-16
Edmonton	CA 009 002	A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy of anti- GITR Monoclonal Antibody (BMS-986156) Administered Alone and in Combination with Nivolumab (BMS- 936558, anti PD-1 Monoclonal Antibody) in Advanced Solid Tumors	Phase I	Phase I/II	NCT02598960	08-Jul-16
Edmonton	CA 209 274	A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma	Genitourinary	Phase III	NCT02632409	13-Sep-16
Edmonton	CA 209 602	An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma	Hematology	Phase III	NCT02726581	28-Nov-16
Edmonton	CA 012 004	A Phase 1/2a Study of BMS-986178 Administered Alone and in Combination with Nivolumab or Ipilimumab in Advanced Solid Tumors	Phase I	Phase I/II	NCT02737475	12-Jan-17
Edmonton	CA 209 649	A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer	Gastrointestinal	Phase III	NCT02872116	01-May-17

City	Protocol	Title	Tumor Group	Trial Phase	NCT	Open Date
Edmonton	CA209-577	A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects With Resected Esophageal, Or Gastroesophageal Junction Cancer	Gastrointestinal	Phase III	NCT02743494	05-Jul-17